News about Global Pharma

FDA Flags Lupin's Pithampur Manufacturing Facility with Official Action Indicated Status

Lupin stated that it is actively engaging with the U.S. regulator and remains committed to maintaining full compliance with current Good Manufacturing Practice (cGMP) standards across all its manufacturing sites.

Global Pharma | 06/10/2025 | By Darshana |  617

Lupin Launches Liraglutide Injection in US

Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use pre-filled pen is bioequivalent to Victoza injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc.

Global Pharma | 04/10/2025 | By Dineshwori |  276

Titan Pharmaceuticals Completes Merger with Black Titan and TalenTec

Titan Pharmaceuticals has completed its merger with Black Titan Corporation, a Cayman Islands exempted company, and TalenTec, a Malaysian private limited company. The transaction closed successfully on October 1, 2025, making Titan a wholly owned subsidiary of Black Titan.

Global Pharma | 04/10/2025 | By Dineshwori |  797

Daiichi Sankyo Establishes Third Research Institute in San Diego

Daiichi Sankyo Research Institutes, located in Boston, Munich and San Diego, are advancing the vision of Daiichi Sankyo to foster the development of next-generation medicines.

Global Pharma | 04/10/2025 | By Dineshwori |  173

India's USD 12 Billion MedTech Sector Set to Surge to USD 50 billion by 2030: Dr Jitendra Singh

Union Minister Dr. Jitendra Singh noted that institutions like SCTIMST, with recognition from WHO and collaborations with national agencies such as ICMR, DBT, CSIR, DRDO and INSA, can contribute to India’s emergence as a global hub for cost-effective healthcare and medical tourism by 2047.

Global Pharma | 04/10/2025 | By Dineshwori |  221

Celltrion Launches Tocilizumab Biosimilar AVTOZMA IV in the US Market

AVTOZMA is Celltrion's fifth immunology biologic and seventh biosimilar approved by the US FDA. It will be available in the same presentations as its reference product, Actemra (tocilizumab).

Global Pharma | 03/10/2025 | By Dineshwori |  528

Lupin Launches Generic Xarelto Rivaroxaban Oral Suspension in US

Global pharma major Lupin has announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States.

Global Pharma | 03/10/2025 | By Dineshwori |  436

Amcor to Showcase Sustainable and Patient-Centric Packaging Innovations at CPHI Frankfurt 2025

At CPHI Frankfurt 2025, Amcor will highlight its extensive portfolio of rigid and flexible packaging solutions, including ClariPPil jars and OSD bottles for oral solid dose applications, alongside its AmSky and high-shield pharma laminates.

Global Pharma | 03/10/2025 | By Dineshwori |  514

FDA Approves Novartis's Rhapsido as First Oral BTK Inhibitor for Chronic Spontaneous Urticaria

The US Food and Drug Administration (FDA) has approved Novartis’ Rhapsido (remibrutinib) as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who continue to experience symptoms despite H1 antihistamine therapy.

Global Pharma | 03/10/2025 | By Dineshwori |  480

Novavax, Sanofi Deepen Partnership to Include Matrix-M in Pandemic Influenza Vaccine Programme

The expanded partnership allows Sanofi to use Novavax’s Matrix-M adjuvant in its pandemic influenza vaccine candidate programme.

Global Pharma | 01/10/2025 | By Dineshwori |  335